Business Context and Reporting Period
This Form 8-K is a current report filed by vTv Therapeutics Inc. on February 28, 2019. The filing discloses a specific corporate event regarding the unregistered sale of equity securities rather than providing periodic financial results.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, or debt levels. The only financial metric disclosed is the capital raise details:
- Capital Raised: $1.5 million
- Shares Issued: 815,217 shares of Class A common stock
- Price Per Share: $1.84
- Investor: MacAndrews & Forbes Group LLC
Material Changes
The material change reported is the execution of a provision within the "December 2018 Letter Agreement." On February 28, 2019, the Company exercised its right to require the Investor to purchase the aforementioned shares. This transaction increased the Company's cash position by $1.5 million and diluted existing shareholders by the issuance of 815,217 new shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure that the transaction terms are qualified by reference to the December 2018 Letter Agreement (Exhibit 10.24 to the 2018 Form 10-K). The Company is identified as an emerging growth company.
Investor Verification Checklist
- Verify the terms of the December 2018 Letter Agreement referenced in the filing.
- Confirm the total number of outstanding shares post-transaction to assess dilution impact.
- Review the Company's 2018 Form 10-K (filed February 26, 2019) for the full context of the financing arrangement.
- Check subsequent filings for the utilization of the $1.5 million raised.